Purdue Pharma could become a public trust funded by OxyContin sales as part of a massive settlement over its role in the opioid epidemic, but some prosecutors and health advocates are skeptical of the idea of relying on profits from the drug that contributed to the crisis.
Purdue, commonly blamed as a major contributor to the opioid epidemic, reportedly could be reorganized through bankruptcy to become a public beneficiary trust, which would give all OxyContin profits to cities, counties, and states and distribute opioid abuse treatments for free.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.